Serum YKL-40 and bone marrow angiogenesis in multiple myeloma

International Journal of Cancer

Volumn 124, Issue 6, 2009, Pages 1492-1494

  Mylin, Anne K ^a   Andersen, Niels F ^b   Johansen, Julia S ^a   Abildgaard, Niels ^c   Helckendorff, Lene ^b   Standal, Therese ^d   Gimsing, Peter ^a   Knudsen, Lene M ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN; INTERLEUKIN 6; SCATTER FACTOR; UNCLASSIFIED DRUG; YKL 40 PROTEIN; CHI3L1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; RNA;

ADULT; AGED; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CLINICAL ARTICLE; CORRELATION ANALYSIS; DENSITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MALE; MICROVASCULATURE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; BLOOD; GENETICS; GLIOBLASTOMA; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NOTE; PATHOLOGY; PHYSIOLOGY; SURVIVAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

BONE MARROW; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MULTIPLE MYELOMA; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; UMBILICAL VEINS;

EID: 60549092917     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24110     Document Type: Letter

References (15)

1. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedom M. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008; 122:2187-98.
2. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa hep-arin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol Chem 1995;270:13076-83.
3. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Ceil Res 2003;287:79-87.
4. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73.
5. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006;20:193-9.
6. Hormigo A, Gu B. Karimi S, Riedel E, Panageas KS. Edgar MA, Tan-war MK, Rao JS, Fleisher M, Deangelis LM, Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12:5698-704.
7. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
8. Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Norgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol 2006;77:416-24.
9. Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N. Syndeean-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005;128:210-7.
10. Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P, Knudsen LM. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol 2008:80:310-317.
11. Hideshima T, Podar K, Chauhan D, Anderson KC, Cytokines and signal transduction. Best Pract Res Clin Haematol 2005; 18:509-24.
12. Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005;208:252-66.
13. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum 2001 ;44:826-37.
14. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injurv. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
15. Matsumoto T, Tsururaoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001; 19:655-60.